Literature DB >> 16826221

A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy.

I Yakoub-Agha1, P Saule, S Depil, J-B Micol, C Grutzmacher, F Boulanger-Villard, F Bauters, J-P Jouet, J-P Dessaint, M Labalette.   

Abstract

CC-chemokine receptor 7 (CCR7), a chemokine receptor required for transmigration into lymphoid organs, is only expressed by naive and central memory T cells. T cells with a capacity of homing into lymphoid organs can initiate acute graft-versus-host disease (GVHD) in mice and respond vigorously in vitro to alloantigens in humans, but their impact on clinical outcomes is unknown. We evaluated prospectively the distribution of naive, central memory and CCR7neg memory T-cell subsets in 39 bone marrow and 23 granulocyte colony-stimulating factor-mobilized peripheral blood stem cell allografts and investigated their impact on patient outcomes. Ranges of the relative proportions of CCR7+ cells within CD4+ and CD8+ T-cell populations were broad, but did not differ between the two sources of allografts. By multivariate analysis, high percentage of donor-derived CD4+CCR7+ T cells (>73.5%) significantly correlated with incidence, earliness of onset and severity of acute GVHD, conferring the highest adjusted hazard ratio (HR=3.9; 95% confidence interval 1.4-10.8; P=0.008) without interfering in other clinical events, especially chronic GVHD and relapse. Determination of the percentage of CD4+CCR7+ T cells in the graft provides a predictive indicator of acute GVHD. Partial depletion of this subset may reduce the risk of acute GVHD while preserving immunotherapeutic effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826221     DOI: 10.1038/sj.leu.2404308

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.

Authors:  Yi-Bin Chen; Haesook T Kim; Sean McDonough; Robert D Odze; Xiaopan Yao; Suzan Lazo-Kallanian; Thomas R Spitzer; Robert Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2009-07-08       Impact factor: 5.742

2.  Donor-derived CD4(+)/CCR7(+) T-cell partial selective depletion does not alter acquired anti-infective immunity.

Authors:  B Choufi; J Trauet; S Thiant; M Labalette; I Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 3.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

4.  Pre-transplant donor CD4- invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease.

Authors:  M-T Rubio; M Bouillié; N Bouazza; T Coman; H Trebeden-Nègre; A Gomez; F Suarez; D Sibon; A Brignier; E Paubelle; S Nguyen-Khoc; M Cavazzana; O Lantz; M Mohty; S Urien; O Hermine
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

Review 5.  Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.

Authors:  Di Zheng; Tejasvini Bhuvan; Natalie L Payne; Tracy S P Heng
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

6.  Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.

Authors:  Katie Matthews; ZiYi Lim; Behdad Afzali; Laurence Pearce; Atiyeh Abdallah; Shahram Kordasti; Antonio Pagliuca; Giovanna Lombardi; J Alejandro Madrigal; Ghulam J Mufti; Linda D Barber
Journal:  Haematologica       Date:  2009-06-02       Impact factor: 9.941

Review 7.  Acute graft-versus-host disease: new treatment strategies.

Authors:  Sophie Paczesny; Sung W Choi; James L M Ferrara
Journal:  Curr Opin Hematol       Date:  2009-11       Impact factor: 3.284

8.  Successful treatment with fingolimod of graft-versus-host disease of the central nervous system.

Authors:  Jordan Gauthier; Patrick Vermersch; Paul Chauvet; Pauline Varlet; Valérie Coiteux; Leonardo Magro; Ibrahim Yakoub-Agha
Journal:  Blood Adv       Date:  2018-01-02

9.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

10.  Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.

Authors:  Sophie Servais; Catherine Menten-Dedoyart; Yves Beguin; Laurence Seidel; André Gothot; Coline Daulne; Evelyne Willems; Loïc Delens; Stéphanie Humblet-Baron; Muriel Hannon; Frédéric Baron
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.